Bahasa

   Home    Contact

A. ORGANISATIONS

1. International League of Association for Rheumatology (www.ilar.org)


 

2. The Asia Pacific League of Associations for Rheumatology (APLAR)



http://www.ilar.org/regionalleagues/aplar.htm

3. The World Health Organization – International League of Associations for Rheumatology
Community Oriented Program for Control Of Rheumatic Disease (WHO-ILAR COPCORD)



http://www.ilar.org/regionalleagues/WHO-ILAR-APLAR%20COPCORD.htm#intteam


3. Lupus Foundation of America, Inc (www.lupus.org)

  

4. American College of Rheumatology (www.rheumatology.org)


5. Australian Rheumatology of Association (www.rheumatology.org.au)

  
 

B. JOURNALS

1. Lupus, An International Journal (www.lupus-journal.com)

  

2. Rheumatology Journal, formerly the British Journal of Rheumatology
    (http://rheumatology.oupjournals.org)

  

3. Journal of Rheumatology (http://www.jrheum.com)

C. OTHERS

1. Lupus Site (www.uklupus.co.uk/lupdat.html)


 

  Email This Page   Print This Page
 
NEWS & EVENTS

LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

16.11.2005
MabThera – a unique approach providing lasting benefits for patients with rheumatoid arthritis

Comprehensive long-term clinical success achieved in difficult-to-treat patients following just two administrations, two weeks apart
 › more
 
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

06.09.2005
Roche files first rheumatoid arthritis indication for MabThera in Europe

MabThera: a medicine used to treat non-Hodgkin's lymphoma

MabThera delivers significant and sustained relief from symptoms in patients with difficult-to-treat rheumatoid arthritis.
› more
 
LupusArthritisIndonesia.org - Indonesian Lupus & Arthritis Forum

06.04.2005
MabThera significantly improves symptoms in patients with rheumatoid arthritis who inadequately responded to anti-TNFα therapies

Third large randomised trial to evaluate efficacy and safety of MabThera in RA

Roche, Genentech and Biogen Idec announced today that REFLEX1, a pivotal Phase III study of MabThera (rituximab), successfully met its primary endpoint in the group of patients with the most difficult-to-treat rheumatoid arthritis (RA).
 › more

Legal Disclamer

Legal Disclaimer

Copyright ©WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases.

This Web site was developed in 2005 as a service provided by the WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases. This Web site provides selected information available about lupus and arthritis. It is important that public see a healthcare professional for detailed information about medical conditions and treatment. This information is not intended to be a substitute for the advice of a healthcare professional, or a recommendation for any particular treatment plan. The WHO-ILAR COPCORD Stage II Education on Treatment of the Autoimmune Diseases has made and will continue to make efforts to include accurate and up-to-date information on this Web site.

If you have any questions, please contact us:
Webmaster
Phone: 62-24-8447-345
Fax: 62-24-8310-028
admin@LupusArthritisIndonesia.org
 


Supported by PT Roche Indonesia